| 10.67 -0.12 (-1.11%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.83 | 1-year : | 14.98 |
| Resists | First : | 10.98 | Second : | 12.83 |
| Pivot price | 10.42  |
|||
| Supports | First : | 9.37 | Second : | 8.37 |
| MAs | MA(5) : | 10.73 |
MA(20) : | 10.12 |
| MA(100) : | 9.57 |
MA(250) : | 8.64 |
|
| MACD | MACD : | 0.3  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 88.6 |
D(3) : | 89.4 |
| RSI | RSI(14): 60.9 |
|||
| 52-week | High : | 11.68 | Low : | 4.32 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRTA ] has closed below upper band by 32.4%. Bollinger Bands are 7.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.79 - 10.86 | 10.86 - 10.91 |
| Low: | 10.32 - 10.4 | 10.4 - 10.46 |
| Close: | 10.56 - 10.68 | 10.68 - 10.77 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Wed, 22 Apr 2026
PRTA SEC Filings - Prothena 10-K, 10-Q, 8-K Forms - Stock Titan
Sun, 12 Apr 2026
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Fri, 10 Apr 2026
Prothena Announces Leadership Team Updates - Business Wire
Fri, 10 Apr 2026
Prothena (PRTA) Chief Strategy Officer reports 66,942 shares and option grants - Stock Titan
Fri, 27 Mar 2026
When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)? - simplywall.st
Tue, 24 Mar 2026
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.965e+007 (%) |
| Held by Institutions | 19.3 (%) |
| Shares Short | 6,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8366e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -129 % |
| Return on Assets (ttm) | 576.1 % |
| Return on Equity (ttm) | -26.4 % |
| Qtrly Rev. Growth | 9.68e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -164 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 7.02e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|